Henkel AG & Co KGaA (HELKF) reports robust financial performance with a 25% EPS increase and announces a significant share ...

XTRA:MRK Earnings and Revenue History March 14th 2025 How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, i ...

ABO Energy GmbH & Co KGaA is expected to close the 2024 financial year with a group net profit of more than EUR 25 million. On 24 November 2024, the company announced in an ad hoc announcement that, ...

In a report released today, Bruno Monteyne from Bernstein maintained a Hold rating on Henkel AG & Co. KGaA (0IZ8 – Research Report), with a ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK".

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...